Aytu BioPharma (AYTU) Financial Ratios: P/E, ROE & More

Aytu BioPharma (AYTU) Financial Ratios

For fiscal 2026 (fiscal year ended Jun 30, 2026), Aytu BioPharma had return on equity of -52.5% (up from -60.8%), debt-to-equity of 0.51 (down from 1.21), a current ratio of 1.13 (down from 1.26) and return on assets of -4.5% (down from 1.3%). A current ratio of 1.13 means current assets exceed current liabilities.

Aytu BioPharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Valuation Ratios
Forward P/E	9.03	9.03	-	-	-	-
P/S Ratio	0.40	0.29	0.27	0.12	0.28	1.92
P/B Ratio	0.65	1.03	0.63	0.23	0.60	0.92
Price/FCF	7.10	-	-	-	-	-
Price/OCF	7.03	-	-	-	-	-
Enterprise Value Ratios
EV/Revenue	0.34	0.36	0.25	0.20	0.21	1.61
EV/EBITDA	-	3.02	2.24	5.92	-	-
EV/EBIT	-	9.43	28.87	-	-	-
EV/FCF	5.93	-	-	-	-	-
Profitability & Returns
Return on Equity (ROE)	-52.55%	-60.76%	-37.33%	-18.05%	-119.62%	-50.12%
Return on Assets (ROA)	-4.53%	1.31%	0.28%	-2.37%	-11.81%	-11.41%
Return on Capital Employed (ROCE)	-16.50%	4.20%	1.00%	-7.70%	-52.10%	-24.50%
Leverage & Solvency Ratios
Debt/Equity	0.51	1.21	0.59	0.47	0.41	0.18
Debt/EBITDA	-	2.68	1.75	4.68	-	-
Debt/FCF	5.57	-	-	-	-	-
Liquidity Ratios
Current Ratio	1.13	1.26	0.99	1.03	0.93	0.96
Quick Ratio	0.90	0.98	0.70	0.75	0.64	0.71
Efficiency Ratios
Asset Turnover	0.50	0.55	0.51	0.54	0.48	0.31
Inventory Turnover	2.27	1.74	1.56	2.23	3.41	2.77
Yield & Distribution Ratios
Earnings Yield	-61.76%	-69.30%	-90.85%	-192.92%	-408.69%	-46.22%
FCF Yield	14.09%	-11.06%	-9.85%	-58.03%	-108.29%	-22.45%
Buyback Yield	-96.17%	-13.40%	-65.81%	-127.22%	-75.54%	-270.57%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Aytu BioPharma Financial Ratios

What is Aytu BioPharma's return on equity?

Aytu BioPharma's return on equity (ROE) was -52.5% for fiscal 2026 (period ended Jun 30, 2026). It was -60.8% a year earlier.

What is Aytu BioPharma's debt-to-equity ratio?

Aytu BioPharma's debt-to-equity ratio was 0.51 for fiscal 2026 (period ended Jun 30, 2026). It was 1.21 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition